Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model

por Jones, Rhys D.O., Petersson, Klas, Tabatabai, Areya, Bao, Larry, Tomkinson, Helen, Schuller, Alwin G.
Publicado 2023

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation

por Henry, Ryan E., Barry, Evan R., Castriotta, Lillian, Ladd, Brendon, Markovets, Aleksandra, Beran, Garry, Ren, Yongxin, Zhou, Feng, Adam, Ammar, Zinda, Michael, Reimer, Corinne, Qing, Weiguo, Su, Weiguo, Clark, Edwin, D'Cruz, Celina M., Schuller, Alwin G.
Publicado 2016

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

por Quackenbush, Kevin S., Bagby, Stacey, Tai, Wai Meng, Messersmith, Wells A., Schreiber, Anna, Greene, Justin, Kim, Jihye, Wang, Guoliang, Purkey, Alicia, Pitts, Todd M., Nguyen, Anna, Gao, Dexiang, Blatchford, Patrick, Capasso, Anna, Schuller, Alwin G., Eckhardt, S. Gail, Arcaroli, John J.
Publicado 2016

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

por Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S., Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E., Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J., Smith, Paul D., Stewart, Ross, Wilkinson, Robert W.
Publicado 2017

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

por Graziano, Vincenzo, Dannhorn, Andreas, Hulme, Heather, Williamson, Kate, Buckley, Hannah, Karim, Saadia A, Wilson, Matthew, Lee, Sheng Y, Kaistha, Brajesh P, Islam, Sabita, Thaventhiran, James E D, Richards, Frances M, Goodwin, Richard, Brais, Rebecca, Morton, Jennifer P, Dovedi, Simon J, Schuller, Alwin G, Eyles, Jim, Jodrell, Duncan I
Publicado 2023

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

por Yang, Rui, Elsaadi, Samah, Misund, Kristine, Abdollahi, Pegah, Vandsemb, Esten Nymoen, Moen, Siv Helen, Kusnierczyk, Anna, Slupphaug, Geir, Standal, Therese, Waage, Anders, Slørdahl, Tobias S, Rø, Torstein Baade, Rustad, Even, Sundan, Anders, Hay, Carl, Cooper, Zachary, Schuller, Alwin G, Woessner, Richard, Borodovsky, Alexandra, Menu, Eline, Børset, Magne, Sponaas, Anne Marit
Publicado 2020

Small molecule AZD4635 inhibitor of A(2A)R signaling rescues immune cell function including CD103(+) dendritic cells enhancing anti-tumor immunity

por Borodovsky, Alexandra, Barbon, Christine M, Wang, Yanjun, Ye, Minwei, Prickett, Laura, Chandra, Dinesh, Shaw, Joseph, Deng, Nanhua, Sachsenmeier, Kris, Clarke, James D, Linghu, Bolan, Brown, Giles A, Brown, James, Congreve, Miles, Cheng, Robert KY, Dore, Andrew S, Hurrell, Edward, Shao, Wenlin, Woessner, Richard, Reimer, Corinne, Drew, Lisa, Fawell, Stephen, Schuller, Alwin G, Mele, Deanna A
Publicado 2020

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

por Booher, Robert N., Hatch, Harold, Dolinski, Brian M., Nguyen, Thi, Harmonay, Lauren, Al-Assaad, Ali-Samer, Ayers, Mark, Nebozhyn, Michael, Loboda, Andrey, Hirsch, Heather A., Zhang, Theresa, Shi, Bin, Merkel, Carrie E., Angagaw, Minilik H., Wang, Yaolin, Long, Brian J., Lennon, Xianlu Q., Miselis, Nathan, Pucci, Vincenzo, Monahan, James W., Lee, Junghoon, Kondic, Anna Georgieva, Im, Eun Kyung, Mauro, David, Blanchard, Rebecca, Gilliland, Gary, Fawell, Stephen E., Zawel, Leigh, Schuller, Alwin G., Strack, Peter
Publicado 2014

Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy

por Patterson, Claire M., Balachander, Srividya B., Grant, Iain, Pop-Damkov, Petar, Kelly, Brian, McCoull, William, Parker, Jeremy, Giannis, Michael, Hill, Kathryn J., Gibbons, Francis D., Hennessy, Edward J., Kemmitt, Paul, Harmer, Alexander R., Gales, Sonya, Purbrick, Stuart, Redmond, Sean, Skinner, Matthew, Graham, Lorraine, Secrist, J. Paul, Schuller, Alwin G., Wen, Shenghua, Adam, Ammar, Reimer, Corinne, Cidado, Justin, Wild, Martin, Gangl, Eric, Fawell, Stephen E., Saeh, Jamal, Davies, Barry R., Owen, David J., Ashford, Marianne B.
Publicado 2021

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

por Tron, Adriana E., Belmonte, Matthew A., Adam, Ammar, Aquila, Brian M., Boise, Lawrence H., Chiarparin, Elisabetta, Cidado, Justin, Embrey, Kevin J., Gangl, Eric, Gibbons, Francis D., Gregory, Gareth P., Hargreaves, David, Hendricks, J. Adam, Johannes, Jeffrey W., Johnstone, Ricky W., Kazmirski, Steven L., Kettle, Jason G., Lamb, Michelle L., Matulis, Shannon M., Nooka, Ajay K., Packer, Martin J., Peng, Bo, Rawlins, Philip B., Robbins, Daniel W., Schuller, Alwin G., Su, Nancy, Yang, Wenzhan, Ye, Qing, Zheng, Xiaolan, Secrist, J. Paul, Clark, Edwin A., Wilson, David M., Fawell, Stephen E., Hird, Alexander W.
Publicado 2018

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

por Eser, Pınar Özden, Paranal, Raymond M., Son, Jieun, Ivanova, Elena, Kuang, Yanan, Haikala, Heidi M., To, Ciric, Okoro, Jeffrey J., Dholakia, Kshiti H., Choi, Jihyun, Eum, Yoonji, Ogino, Atsuko, Missios, Pavlos, Ercan, Dalia, Xu, Man, Poitras, Michael J., Wang, Stephen, Ngo, Kenneth, Dills, Michael, Yanagita, Masahiko, Lopez, Timothy, Lin, Mika, Tsai, Jeanelle, Floch, Nicolas, Chambers, Emily S., Heng, Jennifer, Anjum, Rana, Santucci, Alison D., Michael, Kesi, Schuller, Alwin G., Cross, Darren, Smith, Paul D., Oxnard, Geoffrey R., Barbie, David A., Sholl, Lynette M., Bahcall, Magda, Palakurthi, Sangeetha, Gokhale, Prafulla C., Paweletz, Cloud P., Daley, George Q., Jänne, Pasi A.
Publicado 2021